Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 7,049 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions: Dalbavancin, Dalbavancin-matching Placebo; Drug
Lead sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 25
States / cities: Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more

Conditions: Small Bowel Crohn's Disease
Interventions: Filgotinib, Placebo to match filgotinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Miami, Florida • Orlando, Florida • Tampa, Florida + 12 more

Conditions: Pulmonary Arterial Hypertension
Interventions: QCC374, Placebo Matching; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Stress-related Changes in Inflammation
Interventions: omega-3 supplementation, Oral omega-3 fish oil placebo; Dietary Supplement
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cocaine Dependence
Interventions: D-serine, Cognitive Behavioral Therapy, Placebo; Drug · Behavioral
Lead sponsor: Theresa Winhusen; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Interventions: Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more

Conditions: Schizophrenia
Interventions: TV-46000, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 67
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more

Conditions: Rheumatoid Arthritis
Interventions: GDC-0853, Adalimumab, Folic Acid, MTX, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Interventions: IONIS-AGT-LRx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Little Rock, Arkansas • Crystal River, Florida • Hialeah, Florida + 6 more

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: Rivaroxaban, Placebo, Standard of Care (SOC); Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more

Conditions: Pain, Post-Operative Pain, Third Molar Extraction
Interventions: Ibuprofen 600 mg Extended-Release Tablets, Placebo; Drug
Lead sponsor: SCOLR Pharma, Inc.; Industry
Eligibility: 16 Years to 45 Years
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Overactive Bladder With Urge Urinary Incontinence
Interventions: URO-902, Placebo; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: Mobile, Alabama • Tucson, Arizona • Laguna Hills, California + 17 more

Conditions: Arnica, Third Molar Extraction
Interventions: SinEcch, Placebo; Drug · Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adenomatous Polyposis Coli
Interventions: Erlotinib, Sulindac, Placebo A, Placebo B; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 69 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: NAD, NAD+ Levels in the Blood
Interventions: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, Qualia NAD⁺ version 3, Placebo; Dietary Supplement
Lead sponsor: Qualia Life Sciences; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Ulcerative Colitis
Interventions: Ontamalimab, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 81 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 94
States / cities: Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 80 more

Conditions: Insomnia
Interventions: PD 0200390, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more

Conditions: Alzheimer's Disease
Interventions: T3D-959, Placebo Comparator; Drug · Other
Lead sponsor: T3D Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Myeloid Leukemia
Interventions: Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 6
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 3 more

Conditions: Restless Legs Syndrome
Interventions: Gabapentin Enacarbil (GEn), Placebo; Drug
Lead sponsor: Cleveland Sleep Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Middleburg Heights, Ohio

Conditions: Healthy
Interventions: Investigational Product - MIB 626, Placebo, Standardized, progressive, high intensity, multidimensional exercise, Usual Physical Activity; Drug · Other
Lead sponsor: Metro International Biotech, LLC; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: BIIB078, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 9 more

Conditions: Inflammatory Bowel Disease
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 19 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Mobile, Alabama

Search by objective public record fields.

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

Academic Stress and Proinflammatory Cytokines: Omega-3 Intervention

D-Serine for Cocaine Dependence Pilot

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

Ibuprofen Extended-Release Dental Pain Study

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

Efficacy of Arnica Montana in Reducing Postoperative Edema and Pain

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

Comparison of Three Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy